Logo Logo Logo
  • Faculty
  • Chapter I:
    The Body of Evidence with SGLT-2 inhibitors in cardio-renal risk reduction
    • Cardiovascular Outcomes Trials with SGLT-2 inhibitors
    • SGLT-2 Inhibitors and Heart Failure
    • SGLT-2 Inhibitors and Chronic Kidney Disease
    • Current Guidelines and Recommendations
    • Conclusions
  • Chapter II:
    Translating the Evidence: Patient Cases
    • Case 1
    • Case 2
  • Chapter III:
    Clinical Pearls
  • Chapter IV:
    Additional Resources for Healthcare Providers
  • Chapter V:
    News Digest
    • Article Submission
  • References
Logo Logo Logo Logo Logo
  • Faculty
  • Chapter I:
    The Body of Evidence with SGLT-2 inhibitors in cardio-renal risk reduction
    • Cardiovascular Outcomes Trials with SGLT-2 inhibitors
    • SGLT-2 Inhibitors and Heart Failure
    • SGLT-2 Inhibitors and Chronic Kidney Disease
    • Current Guidelines and Recommendations
    • Conclusions
  • Chapter II:
    Translating the Evidence: Patient Cases
    • Case 1
    • Case 2
  • Chapter III:
    Clinical Pearls
  • Chapter IV:
    Additional Resources for Healthcare Providers
  • Chapter V:
    News Digest
    • Article Submission
  • References

Chapter I: The relationship between HF, CKD, and T2DM

Topic 1

Memorable text quote

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  1. Detail 1
  2. Detail 2
  3. Detail 3
  • Legend One

  • Legend Two

  • Legend Three

What is the first letter of the alphabet?
Vote

Article Submission

Cardiometabolic Chronicle, the official publication of the Cardiometabolic Health Congress®, welcomes the submission of articles on diverse topics of cardiometabolic health that are relevant to the mission of CMHC. These may include original thought pieces, editorials, clinical pearls, clinical trends and breakthroughs, patient perspectives, and more. Please note that Cardiometabolic Chronicle does not accept primary original research.






I give permission for your article to be published in the Cardiometabolic Chronicle (required)

Case A
Case B
Symptom
Symptom
Symptom
Symptom 2
Symptom 2
Symptom 2
Course Progress0%
Continue to chapter 2
Click here to see the chapter list!

For support contact support@amerra.com

COPYRIGHT © 2020 Cardiometabolic Health Congress. All Rights Reserved.